Physician profile
Stephanie E Tyson
NPI 1356185680
$790.58
in general payments reported to CMS, 2019-2025
20 companies · $649 in 2025
The $649 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $142 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.73 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $148.59 | 2025 | |
| Pfizer INC. | $107.31 | 2024-2025 | |
| Novo Nordisk INC | $80.92 | 2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $60.89 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Seqirus USA INC | $38.64 | 2025 | Fluad, Flucelvax |
| Amgen INC. | $38.22 | 2024-2025 | Evenity, Prolia, Otezla |
| Boston Scientific Corporation | $37.24 | 2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.69 | 2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $30.56 | 2025 | Unithroid |
| Phadia US INC. | $28.87 | 2025 | Immunocap |
| Philips North America LLC | $21.81 | 2024 | (Ck6) Holter |
| Phathom Pharmaceuticals, INC. | $20.38 | 2025 | Voquezna |
| Abbott Laboratories | $19.56 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.56 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $19.01 | 2024 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $18.39 | 2024 | Uptravi, Opsumit |
| Xeris Pharmaceuticals, INC. | $17.24 | 2025 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $16.76 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $16.75 | 2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $16.19 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.